David R. Bauer
Lawyers
Filters
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
OPKO Health $230 million convertible senior notes offering
The 3.75% convertible notes are due 2029
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
GSK exclusive license agreement for HS-20093 with Hansoh Pharma
We advised GSK on the transaction
Merit Medical Systems $747.5 million convertible senior notes offering
The 3% convertible senior notes are due 2029
Integral Ad Science $152.8 million secondary offering
The stock is listed on the Nasdaq Global Select Market
Smith+Nephew acquisition of CartiHeal
We are advising Smith+Nephew on the acquisition
Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
NeuroPace $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction